Charles River Laboratories International, Inc. (CRL) Stock Analysis
Charles River is repositioning into a leaner, higher-margin preclinical powerhouse, with BIOSECURE-driven share gains and scarce NHP supply control creating a compelling long-term setup.
Overview
Charles River Laboratories is a leading global preclinical CRO serving biopharma, biotech, academic, government, agricultural, and chemical customers across drug discovery, safety assessment, research models, and manufacturing testing. Revenue is primarily service-based and recurring, with DSA representing the largest segment. Its competitive advantage comes from scale, regulatory expertise, integrated services, and the ability to reduce hand-off risk for complex preclinical programs. North America and Europe dominate revenue, while Asia-Pacific remains a growth market. The company is positioned as a core infrastructure provider to the drug development ecosystem.